Steve Pakola Sells 36,725 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 36,725 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total transaction of $472,283.50. Following the transaction, the insider owned 213,009 shares in the company, valued at $2,739,295.74. This trade represents a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The stock was sold at an average price of $11.04, for a total transaction of $216,472.32.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $13.28 on Friday. REGENXBIO Inc. has a 1 year low of $5.45 and a 1 year high of $16.19. The firm’s 50-day simple moving average is $8.21 and its 200-day simple moving average is $9.91. The firm has a market cap of $686.58 million, a PE ratio of -2.37 and a beta of 0.90.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The firm had revenue of $6.39 million during the quarter, compared to analyst estimates of $25.84 million. On average, equities analysts predict that REGENXBIO Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Robert W. Baird upped their price target on REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, June 22nd. Leerink Partners lifted their price objective on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Barclays dropped their target price on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, May 15th. Finally, Morgan Stanley set a $16.00 price target on shares of REGENXBIO in a research report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.82.

Institutional Trading of REGENXBIO

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in shares of REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares during the period. Assenagon Asset Management S.A. grew its position in shares of REGENXBIO by 64.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock worth $16,709,000 after acquiring an additional 454,977 shares during the last quarter. Invenomic Capital Management LP acquired a new stake in shares of REGENXBIO in the 3rd quarter worth about $4,120,000. Integral Health Asset Management LLC lifted its position in REGENXBIO by 57.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $10,615,000 after purchasing an additional 400,000 shares during the last quarter. Finally, State Street Corp lifted its position in REGENXBIO by 15.2% in the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock valued at $32,929,000 after purchasing an additional 301,858 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.